RxDoctor Payments Data

Bradford Quatkemeyer, MD

Family Medicine · Crittenden, KYNPI 1942261250

Payments from drug & device makers

$5,072in general payments, 2019–2025

Across 317 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$644
  • GSK$338
  • Pfizer$310
  • Lilly USA, LLC$246
  • Amgen$197
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,072 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$71,283
Medicare patients
295
Services billed
3,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$110,338
OzempicSemaglutide65$72,633
CreonLipase/Protease/Amylase11$64,414
JardianceEmpagliflozin58$57,695
MounjaroTirzepatide30$54,912
TrulicityDulaglutide36$53,263
Nurtec OdtRimegepant Sulfate28$35,362
XareltoRivaroxaban35$33,904
RybelsusSemaglutide22$33,240
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$29,057
LinzessLinaclotide36$23,168
FarxigaDapagliflozin Propanediol28$17,841
JanuviaSitagliptin Phosphate28$17,796
MyrbetriqMirabegron24$16,178
EntrestoSacubitril/Valsartan20$15,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$310$145,700163 claims
Lilly USA, LLCMounjaro, Trulicity$246$108,17566 claims
Novo NordiskOzempic, Rybelsus$644$105,87387 claims
AbbVieCreon, Linzess$1,095$87,58247 claims
Boehringer IngelheimJardiance$14$57,69558 claims
GSKTrelegy Ellipta, Anoro Ellipta$338$40,61856 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$167$36,21563 claims
Johnson & JohnsonXarelto$84$33,90435 claims
MerckJanuvia$31$17,79628 claims
Astellas Pharma US IncMyrbetriq$87$16,17824 claims
NovartisEntresto$87$15,79620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Crittenden

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →